Skip to main content

Advertisement

Table 2 Characteristics of brain metastases according to breast cancer subtype and trastuzumab treatment before brain metastases development

From: Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes

  HR-positive/HER2-negative (N=45) HER2-positive TNBC(N=58) P-value
Without T*(N=39) With T*(N=47)
Age, median (range)      
 At initial distant mets 49 (30–85) 45 (25–68)) 46 (33–66) 44 (26–65) 0.145
 At BM diagnosis 51 (30–87) 46 (26–70) 50 (34–67) 45 (26–67) 0.005
Stage at initial diagnosis      0.088
 I/II 27 (61%) 14 (38%) 15 (30%) 25 (43%)  
 III 11 (23%) 19 (48%) 22 (48%) 24 (41%)  
 IV 4 (9%) 1 (2%) 7 (15%) 6 (10%)  
 unknown 3 (7%) 5 (12%) 3 (7%) 3 (5%)  
Brain as initial metastatic site 9 (21%) 15 (37%) 10 (21%) 22 (38%) 0.112
Brain,the only metastatic site 5 (11%) 4 (10%) 6 (13%) 12 (21%) 0.142
Site of initial distant metastasis      
 Bone 18 (47%) 18 (50%) 15 (44%) 21 (38%) 0.705
 Lung 14 (37%) 14 (39%) 11 (32%) 26 (47%) 0.535
 Liver 5 (13%) 6 (17%) 13 (38%) 8 (15%) 0.036
 Pleura 7 (18%) 5 (13%) 5 (16%) 8 (15%) 0.936
LMS at BM diagnosis 7 (17%) 6 (15%) 6 (16%) 12 (21%) 0.824
ECOG PS at BM diagnosis     0.482
 0-1 32 (72%) 27 (69%) 33 (70%) 35 (60%)  
 2 5 (12%) 6 (16%) 10 (22%) 13 (22%)  
 3-4 8 (19%) 5 (14%) 4 (9%) 10 (17%)  
Number of brain metastasis     0.430
 1 16 (36%) 10 (26%) 8 (17%) 17 (29%)  
 2-3 3 (7%) 8(21%) 8 (17%) 9 (16%)  
 ≥3 24 (53%) 20 (51%) 31 (66%) 31 (53%)  
missing 2 (4%) 1(3%) 0(0%) 1 (2%)  
Extracranial systemic control at BM diagnosis      0.122
 PR/SD 7 (16%) 6 (15%) 16 (34%) 9 (16%)  
 PD 27 (60%) 25 (64%) 20 (43%) 37 (64%)  
 No other systemic mets. 5 (11%) 4 (10%) 6 (13%) 12 (21%)  
 unknown 6 (13%) 4 (10%) 5 (11%) 0 (0%)  
  1. *T; trastuzumab, TNBC; triple negative breast cancer, LMS; leptomeningeal seeding.